22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Evidence for Effective Multiple K +-Current Inhibitions by Tolvaptan, a Non-peptide Antagonist of Vasopressin V 2 Receptor

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tolvaptan (TLV), an oral non-peptide antagonist of vasopressin V 2 receptor, has been increasingly used for managements in patients with hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion. However, none of the studies have thus far been investigated with regard to its possible perturbations on membrane ion currents in endocrine or neuroendocrine cells. In our electrophysiological study, the whole-cell current recordings showed that the presence of TLV effectively and differentially suppressed the amplitude of delayed rectifier K + ( I K(DR)) and M-type K + current ( I K(M)) in pituitary GH 3 cells with an IC 50 value of 6.42 and 1.91 μM, respectively. This compound was also capable of shifting the steady-state activation curve of I K(M) to less depolarized potential without any appreciable change in the gating charge of this current. TLV at a concentration greater than 10 μM also suppressed the amplitude of erg-mediated K + current or the activity of large-conductance Ca 2+-activated K + channels; however, this compound failed to alter the amplitude of hyperpolarization-activated cation current in GH 3 cells. In vasopressin-preincubated GH 3 cells, TLV-mediated suppression of I K(M) remained little altered. Under current-clamp condition, we also observed that addition of TLV increased the firing of spontaneous action potentials in GH 3 cells and further addition of flupirtine could reverse TLV-mediated elevation of the firing. In Madin-Darby canine kidney (MDCK) cells, the K + current elicited by long ramp pulse was also effectively subject to inhibition by this compound. Findings from the present study were thus stated as saying that the suppression by TLV of multiple type K + currents could be direct and independent of its antagonism of vasopressin V 2 receptors. Our study also reveals an important aspect that should be considered when assessing aquaretic effect of TLV or its structurally similar compounds.

          Related collections

          Most cited references67

          • Record: found
          • Abstract: found
          • Article: not found

          Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

          In a previous trial involving patients with early autosomal dominant polycystic kidney disease (ADPKD; estimated creatinine clearance, ≥60 ml per minute), the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume and the decline in the estimated glomerular filtration rate (GFR) but also caused more elevations in aminotransferase and bilirubin levels. The efficacy and safety of tolvaptan in patients with later-stage ADPKD are unknown.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing.

            Analysis of the Kv3 subfamily of K(+) channel subunits has lead to the discovery of a new class of neuronal voltage-gated K(+) channels characterized by positively shifted voltage dependencies and very fast deactivation rates. These properties are adaptations that allow these channels to produce currents that can specifically enable fast repolarization of action potentials without compromising spike initiation or height. The short spike duration and the rapid deactivation of the Kv3 currents after spike repolarization maximize the quick recovery of resting conditions after an action potential. Several neurons in the mammalian CNS have incorporated into their repertoire of voltage-dependent conductances a relatively large number of Kv3 channels to enable repetitive firing at high frequencies - an ability that crucially depends on the special properties of Kv3 channels and their impact on excitability.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan

              In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information approved by the FDA provides helpful guidelines but does not address practical questions that are being raised by nephrologists, internists, and general practitioners taking care of patients with ADPKD, and by the patients themselves. In this review, we provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively. These steps include confirmation of diagnosis; identification of rapidly progressive disease; implementation of basic renal protective measures; counseling of patients on potential benefits and harms; exclusions to use; education of patients on aquaresis and its expected consequences; initiation, titration, and optimization of tolvaptan treatment; prevention of aquaresis-related complications; evaluation and management of liver enzyme elevations; and monitoring of treatment efficacy. Our recommendations are made on the basis of published evidence and our collective experiences during the randomized, clinical trials and open-label extension studies of tolvaptan in ADPKD.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                18 February 2019
                2019
                : 10
                : 76
                Affiliations
                [1] 1School of Pharmacy, China Medical University , Taichung, Taiwan
                [2] 2Division of Cardiovascular Medicine, Chi-Mei Medical Center , Tainan, Taiwan
                [3] 3Department of Nephrology, Chang Bing Show Chwan Memorial Hospital , Changhua, Taiwan
                [4] 4Department of Physiology, National Cheng Kung University Medical College , Tainan, Taiwan
                [5] 5Institute of Basic Medical Sciences, National Cheng Kung University Medical College , Tainan, Taiwan
                Author notes

                Edited by: Yasuo Mori, Kyoto University, Japan

                Reviewed by: Hiroshi Hibino, Niigata University, Japan; Guillaume Eric Sandoz, INSERM U1091 Institut de Biologie de Valrose, France

                *Correspondence: Sheng-Nan Wu snwu@ 123456mail.ncku.edu.tw

                This article was submitted to Pharmacology of Ion Channels and Channelopathies, a section of the journal Frontiers in Pharmacology

                Article
                10.3389/fphar.2019.00076
                6401633
                30873020
                fdea33a6-37ea-4f5c-9d6f-4422ae2d7a5b
                Copyright © 2019 Lu, Chang, Chan and Wu.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 29 November 2018
                : 21 January 2019
                Page count
                Figures: 8, Tables: 0, Equations: 2, References: 70, Pages: 13, Words: 9863
                Categories
                Pharmacology
                Original Research

                Pharmacology & Pharmaceutical medicine
                tolvaptan,m-type k+ current,delayed-rectifier k+ current,erg-mediated k+ current,membrane potential,pituitary cell,renal epithelial cell

                Comments

                Comment on this article